ALung Technologies, Inc. was founded in 1997 by Dr. William Federspiel and the late Dr. Brack Hattler with the mission of commercializing innovative medical devices for patients with acute respiratory failure. ALung is privately financed.
A Unique Opportunity
The worldwide market opportunity for ALung’s products is estimated to be $4.6 billion. Currently there are no other devices on the market which permit simple extracorporeal CO2 removal like the Hemolung RAS.
ALung’s patented Hemolung technology is truly revolutionary. The Hemolung Cartridge is the core of the system. The cartridge utilizes an innovative and proprietary “active mixing” design to achieve significantly higher gas exchange efficiency than currently available “passive” oxygenators. ALung owns or has the rights to 7 issued and 3 pending patents in the field of respiratory support devices with broad method protection and significant trade secrets associated with the Hemolung Cartridge and Controller.
An Experienced Team
ALung is led by a team of experienced medical device executives with diverse backgrounds in business, engineering, and regulatory affairs. Since the inception of ALung, management has raised approximately $40M in private equity. The company has also successfully secured over $5M in grants.
This website may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.